JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Immunology Année : 2023

JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study

Caroline Espil
  • Fonction : Auteur
Pascal Pillet
  • Fonction : Auteur
Anne Hulin
  • Fonction : Auteur

Résumé

The paradigm type I interferonopathy Aicardi-Goutières syndrome (AGS) is most typically characterized by severe neurological involvement. AGS is considered an immune-mediated disease, poorly responsive to conventional immunosuppression. Premised on a chronic enhancement of type I interferon signaling, JAK1/2 inhibition has been trialed in AGS, with clear improvements in cutaneous and systemic disease manifestations. Contrastingly, treatment efficacy at the level of the neurological system has been less conclusive. Here, we report our real-word approach study of JAK1/2 inhibition in 11 patients with AGS, providing extensive assessments of clinical and radiological status; interferon signaling, including in cerebrospinal fluid (CSF); and drug concentrations in blood and CSF. Over a median follow-up of 17 months, we observed a clear benefit of JAK1/2 inhibition on certain systemic features of AGS, and reproduced results reported using the AGS neurologic severity scale. In contrast, there was no change in other scales assessing neurological status; using the caregiver scale, only patient comfort, but no other domain of everyday-life care, was improved. Serious bacterial infections occurred in 4 out of the 11 patients. Overall, our data lead us to conclude that other approaches to treatment are urgently required for the neurologic features of AGS. We suggest that earlier diagnosis and adequate central nervous system penetration likely remain the major factors determining the efficacy of therapy in preventing irreversible brain damage, implying the importance of early and rapid genetic testing and the consideration of intrathecal drug delivery.
Fichier principal
Vignette du fichier
s10875-023-01500-z.pdf (3.38 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

pasteur-04124249 , version 1 (09-06-2023)

Licence

Identifiants

Citer

Marie-Louise Frémond, Marie Hully, Benjamin Fournier, Rémi Barrois, Romain Lévy, et al.. JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study. Journal of Clinical Immunology, 2023, ⟨10.1007/s10875-023-01500-z⟩. ⟨pasteur-04124249⟩
20 Consultations
49 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More